On the basis of these results, we can conclude that grade 2 bladder cancer and TNBC represent good models to test ATF-SAP biological activity; furthermore, ATF targeting domain is absolutely required to increase the toxin selectivity on uPAR+ cells in in vitro assays. The gene discussed is PLAU; the disease is urinary bladder carcinoma.